Covishield Booster Dose

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

The usage of Covishield has been the highest as the precaution dose for COVID-19 as compared to other vaccines, said Union Health Ministry sources on Tuesday.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.

Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.

Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.

Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.

There will be no mix-and-match of vaccines for those eligible to get a 'precautionary' third dose, Dr VK Paul, the head of India's Covid task force, said Wednesday, meaning those who got Covishield will get the same, as will those who got Covaxin.

Indian students in the United Kingdom who have received two doses of AstraZeneca's Covishield vaccine will be able to get a booster shot, as per the new protocol announced by British Prime Minister Boris Johnson.

An expert panel of India's central drug authority reviewed Serum Institute's application for approval of Covishield as booster dose against COVID-19 on Friday.

Adar Poonawalla, the chief of Serum Institute which is manufacturing Covishield, today said the billionth dose of coronavirus vaccine is a milestone for India and over the next two months, the country will catch up further. There is even a possibili

Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.

The ideal gap between two doses of Covishield is two months and another dose of the vaccine should be taken after six months, the Serum Institute of India (SII) chairman Cyrus Poonawalla said on Friday.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

The usage of Covishield has been the highest as the precaution dose for COVID-19 as compared to other vaccines, said Union Health Ministry sources on Tuesday.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.

Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.

Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.

Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.

There will be no mix-and-match of vaccines for those eligible to get a 'precautionary' third dose, Dr VK Paul, the head of India's Covid task force, said Wednesday, meaning those who got Covishield will get the same, as will those who got Covaxin.

Indian students in the United Kingdom who have received two doses of AstraZeneca's Covishield vaccine will be able to get a booster shot, as per the new protocol announced by British Prime Minister Boris Johnson.

An expert panel of India's central drug authority reviewed Serum Institute's application for approval of Covishield as booster dose against COVID-19 on Friday.

Adar Poonawalla, the chief of Serum Institute which is manufacturing Covishield, today said the billionth dose of coronavirus vaccine is a milestone for India and over the next two months, the country will catch up further. There is even a possibili

Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.

The ideal gap between two doses of Covishield is two months and another dose of the vaccine should be taken after six months, the Serum Institute of India (SII) chairman Cyrus Poonawalla said on Friday.